Effects of treatment with beclomethasone dipropionate in subpopulations of perennial rhinitis patients.
The efficacy and safety of beclomethasone dipropionate (BD), 0.05 mg three times daily, sprayed in each nostril was studied in 39 adult patients with perennial rhinitis in a 12 wk, double-blind, vehicle controlled trial. Parameters of IgE-mediated reactivity, including epicutaneous skin testing, total serum IgE, specific serum IgE, and nasal eosinophilia, were assessed. All adverse reactions, including changes in serum cortisol and nasal and pharyngeal Candida infections, were monitored. Sixty-three percent of BD patients achieved total or substantial control of nasal symptoms compared with 25% of controls (p = 0.04). Eighty-three percent of BD-treated, skin test-positive patients improved, while only 14% of BD nonatopics improved (p less than 0.05). All BD patients with nasal eosinophilia improved compared with 38% without eosinophilia. Adverse reactions were frequent, minor, and equal in both groups. Serum cortisols were stable and no nasal Candida infections were documented. This study demonstrates the efficacy and safety of BD in treatment of perennial rhinitis, particularly in atopic patients with nasal eosinophilia.
D000293:Adolescent; D000328:Adult; D001507:Beclomethasone / Q000009:adverse effects / Q000627:therapeutic use*; D004802:Eosinophilia / Q000175:diagnosis / Q000209:etiology; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000166:cytology; D011852:Radioallergosorbent Test; D012221:Rhinitis, Allergic, Perennial / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012882:Skin Tests
D007073:Immunoglobulin E; D001507:Beclomethasone